Jinling Pharmaceutical Co Ltd (000919) — Cash Flow-to-Debt Ratio
Jinling Pharmaceutical Co Ltd (000919) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of CN¥74.01 Million could theoretically repay 0% of its total liabilities (CN¥1.18 Billion) in one year. See financial agility of Jinling Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jinling Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1999–2024)
Historical debt coverage capacity for Jinling Pharmaceutical Co Ltd across 26 annual periods. For the full cash flow conversion analysis, see Jinling Pharmaceutical Co Ltd (000919) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Jinling Pharmaceutical Co Ltd (1999–2024)
Year-by-year debt coverage analysis for Jinling Pharmaceutical Co Ltd. Check earnings quality score of Jinling Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.12x | CN¥154.19 Million | CN¥1.24 Billion | ▼ -32.3% |
| 2023 | 0.18x | CN¥158.92 Million | CN¥865.58 Million | ▼ -35.4% |
| 2022 | 0.28x | CN¥260.59 Million | CN¥916.30 Million | ▼ -11.1% |
| 2021 | 0.32x | CN¥292.03 Million | CN¥913.10 Million | ▼ -12.7% |
| 2020 | 0.37x | CN¥311.46 Million | CN¥850.43 Million | ▼ -42.3% |
| 2019 | 0.63x | CN¥465.85 Million | CN¥733.62 Million | ▼ -6.5% |
| 2018 | 0.68x | CN¥433.83 Million | CN¥638.90 Million | ▲ +23.1% |
| 2017 | 0.55x | CN¥443.11 Million | CN¥803.11 Million | ▲ +361.9% |
| 2016 | 0.12x | CN¥96.15 Million | CN¥804.90 Million | ▼ -47.9% |
| 2015 | 0.23x | CN¥212.45 Million | CN¥925.73 Million | ▼ -33.3% |
| 2014 | 0.34x | CN¥299.89 Million | CN¥871.24 Million | ▼ -7.4% |
| 2013 | 0.37x | CN¥271.21 Million | CN¥729.94 Million | ▲ +17.4% |
| 2012 | 0.32x | CN¥232.12 Million | CN¥733.12 Million | ▲ +16.0% |
| 2011 | 0.27x | CN¥172.82 Million | CN¥633.01 Million | ▼ -16.4% |
| 2010 | 0.33x | CN¥177.81 Million | CN¥544.47 Million | ▼ -30.6% |
| 2009 | 0.47x | CN¥188.41 Million | CN¥400.59 Million | ▼ -50.0% |
| 2008 | 0.94x | CN¥305.26 Million | CN¥324.25 Million | ▲ +232.4% |
| 2007 | 0.28x | CN¥118.06 Million | CN¥416.86 Million | ▼ -32.4% |
| 2006 | 0.42x | CN¥138.50 Million | CN¥330.39 Million | ▲ +7.6% |
| 2005 | 0.39x | CN¥109.29 Million | CN¥280.42 Million | ▼ -21.3% |
| 2004 | 0.50x | CN¥159.81 Million | CN¥322.83 Million | ▼ -21.7% |
| 2003 | 0.63x | CN¥161.86 Million | CN¥256.06 Million | ▲ +43.9% |
| 2002 | 0.44x | CN¥130.36 Million | CN¥296.79 Million | ▲ +45.6% |
| 2001 | 0.30x | CN¥92.49 Million | CN¥306.54 Million | ▼ -79.0% |
| 2000 | 1.43x | CN¥231.31 Million | CN¥161.37 Million | ▲ +452.4% |
| 1999 | 0.26x | CN¥39.77 Million | CN¥153.24 Million | — |